Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aravive Biologics Expands Scientific and Clinical Advisory Team
Aravive Biologics, Inc., a clinical-stage biotechnology company focused on development of treatments for cancer and fibrotic diseases, today announced two new appointments to the company’s scientific advisory board. Kimberly L. Blackwell, M.D., Vice President, Early Phase Oncology and
View HTML
Toggle Summary Aravive Biologics Initiates Phase 1 Study of Novel GAS6-AXL Pathway Inhibitor, AVB-S6-500
Aravive Biologics, Inc., a clinical-stage biotechnology company focused on development of treatments for cancer and fibrotic diseases, today announced the initiation of a Phase 1 clinical trial of AVB-S6-500 (previously referred to as Aravive-S6).  The study is being conducted in the United States
View HTML
Toggle Summary Aravive Biologics and WuXi Biologics to Form Strategic Manufacturing Collaboration Following Successful IND Filing for AVB-S6-500
Aravive Biologics, Inc. and WuXi Biologics (WuXi Bio, 02269.HK) today announced plans to expand their biologics manufacturing collaboration, based on the rapid success achieved in the process development, scale-up and cGMP manufacture of Aravive’s lead drug candidate, AVB-S6-500 (previously
View HTML